skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 {<=}90 U/mL and Comparison to the CONKO-001 Trial

Abstract

Purpose: Radiation Therapy Oncology Group (RTOG) trial 9704 was the largest randomized trial to use adjuvant chemoradiation therapy for patients with pancreatic cancer. This report analyzes 5-year survival by serum level of tumor marker CA 19-9 of {<=}90 vs >90 U/mL and compares results to the those of the CONKO-001 trial. Methods and Materials: CA 19-9 expression was analyzed as a dichotomized variable ({<=}90 vs >90 U/mL). Cox proportional hazard models were used to identify the impact of the CA 19-9 value on overall survival (OS). Actuarial estimates of OS were calculated using the Kaplan-Meier method. Results: Both univariate (hazard ratio [HR] = 3.2; 95% confidence interval [CI], 2.3-4.3, P<.0001) and multivariate (HR = 3.1; 95% CI, 2.2-4.2, P<.0001) analyses demonstrated a statistically significant decrease in OS for CA 19-9 serum level of {>=}90 U/mL. For patients in the gemcitabine (Gem) treatment arm with CA 19-9 <90 U/mL, median survival was 21 months. For patients with CA 19-9 {>=}90 U/mL, this number dropped to 10 months. In patients with pancreatic head tumors in the Gem treatment arm with RT quality assurance per protocol and CA 19-9 of <90 U/mL, median survival and 5-year rate were 24 months and 34%. Inmore » comparison, the median survival and 5-year OS rate for patients in the Gem arm of the CONKO trial were 22 months and 21%. Conclusions: This analysis demonstrates that patients with postresection CA 19-9 values {>=}90 U/mL had a significantly worse survival. Patients with pancreatic head tumors treated with Gem with CA 19-9 serum level of <90 U/mL and per protocol RT had favorable survival compared to that seen in the CONKO trial. CA 19-9 is a stratification factor for the current RTOG adjuvant pancreas trial (0848).« less

Authors:
 [1];  [2];  [3];  [4];  [5];  [6];  [3];  [7];  [8];  [9]
  1. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania (United States)
  2. RTOG Statistical Center, Philadelphia, Pennsylvania (United States)
  3. Fox Chase Cancer Center, Philadelphia, Pennsylvania (United States)
  4. University of Maryland Medical Systems, Baltimore, Maryland (United States)
  5. Rush University Medical Center, Chicago, Illinois (United States)
  6. Division of Hematology/Oncology, The Miriam Hospital, Providence, Rhode Island (United States)
  7. Northwestern Memorial Hospital, Chicago, Illinois (United States)
  8. St. Vincent's Comprehensive Cancer Center, New York, New York (United States)
  9. Duke University Medical Center, Durham, North Carolina (United States)
Publication Date:
OSTI Identifier:
22149573
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 84; Journal Issue: 3; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; COMPARATIVE EVALUATIONS; HEALTH HAZARDS; MULTIVARIATE ANALYSIS; NEOPLASMS; PANCREAS; PATIENTS; QUALITY ASSURANCE; RADIOTHERAPY; STRATIFICATION

Citation Formats

Berger, Adam C., E-mail: adam.berger@jefferson.edu, Winter, Kathryn, Hoffman, John P., Regine, William F., Abrams, Ross A., Safran, Howard, Freedman, Gary M., Benson, Alan B., MacDonald, John, and Willett, Christopher G. Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 {<=}90 U/mL and Comparison to the CONKO-001 Trial. United States: N. p., 2012. Web. doi:10.1016/J.IJROBP.2012.04.035.
Berger, Adam C., E-mail: adam.berger@jefferson.edu, Winter, Kathryn, Hoffman, John P., Regine, William F., Abrams, Ross A., Safran, Howard, Freedman, Gary M., Benson, Alan B., MacDonald, John, & Willett, Christopher G. Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 {<=}90 U/mL and Comparison to the CONKO-001 Trial. United States. doi:10.1016/J.IJROBP.2012.04.035.
Berger, Adam C., E-mail: adam.berger@jefferson.edu, Winter, Kathryn, Hoffman, John P., Regine, William F., Abrams, Ross A., Safran, Howard, Freedman, Gary M., Benson, Alan B., MacDonald, John, and Willett, Christopher G. Thu . "Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 {<=}90 U/mL and Comparison to the CONKO-001 Trial". United States. doi:10.1016/J.IJROBP.2012.04.035.
@article{osti_22149573,
title = {Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 {<=}90 U/mL and Comparison to the CONKO-001 Trial},
author = {Berger, Adam C., E-mail: adam.berger@jefferson.edu and Winter, Kathryn and Hoffman, John P. and Regine, William F. and Abrams, Ross A. and Safran, Howard and Freedman, Gary M. and Benson, Alan B. and MacDonald, John and Willett, Christopher G.},
abstractNote = {Purpose: Radiation Therapy Oncology Group (RTOG) trial 9704 was the largest randomized trial to use adjuvant chemoradiation therapy for patients with pancreatic cancer. This report analyzes 5-year survival by serum level of tumor marker CA 19-9 of {<=}90 vs >90 U/mL and compares results to the those of the CONKO-001 trial. Methods and Materials: CA 19-9 expression was analyzed as a dichotomized variable ({<=}90 vs >90 U/mL). Cox proportional hazard models were used to identify the impact of the CA 19-9 value on overall survival (OS). Actuarial estimates of OS were calculated using the Kaplan-Meier method. Results: Both univariate (hazard ratio [HR] = 3.2; 95% confidence interval [CI], 2.3-4.3, P<.0001) and multivariate (HR = 3.1; 95% CI, 2.2-4.2, P<.0001) analyses demonstrated a statistically significant decrease in OS for CA 19-9 serum level of {>=}90 U/mL. For patients in the gemcitabine (Gem) treatment arm with CA 19-9 <90 U/mL, median survival was 21 months. For patients with CA 19-9 {>=}90 U/mL, this number dropped to 10 months. In patients with pancreatic head tumors in the Gem treatment arm with RT quality assurance per protocol and CA 19-9 of <90 U/mL, median survival and 5-year rate were 24 months and 34%. In comparison, the median survival and 5-year OS rate for patients in the Gem arm of the CONKO trial were 22 months and 21%. Conclusions: This analysis demonstrates that patients with postresection CA 19-9 values {>=}90 U/mL had a significantly worse survival. Patients with pancreatic head tumors treated with Gem with CA 19-9 serum level of <90 U/mL and per protocol RT had favorable survival compared to that seen in the CONKO trial. CA 19-9 is a stratification factor for the current RTOG adjuvant pancreas trial (0848).},
doi = {10.1016/J.IJROBP.2012.04.035},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 3,
volume = 84,
place = {United States},
year = {2012},
month = {11}
}